Highest-materiality recent filing
Phio Pharma Q2 net loss $4.1M; cash $13.0M; PH-762 Phase 1b completed
Net loss of $4.1M for Q2 2026 vs $2.2M in Q2 2025, driven by higher R&D spend.
Phio Pharmaceuticals appoints Dr. R. Todd Plott to Board of Directors
Board size increased to six members; Dr. Plott appointed effective July 20, 2026 until 2026 annual meeting.
Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety
Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M
Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.
Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response
Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.
Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%
CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.
No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.
Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance
22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.
Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026
FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.
Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses
18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.
Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose
Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.
Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares
Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.
Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe
100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.
Director Robert Ferrara resigns; David Deming appointed Lead Independent Director
Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.
All six director nominees elected with 84-94% of votes cast; 1,828,465 broker non-votes.
Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference
Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).
Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort
Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.
Phio Pharma receives ~$2.5M from warrant exercise, issues new warrants
Gross proceeds ~$2.5M from exercise of 928,596 warrants at $2.00 and $2.485 per share.
Phio reports complete response in cSCC and manufacturing agreement for PH-762
Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.
Phio sets 2025 annual meeting for Sept 11; new proposal deadlines
Annual meeting on Sept 11, 2025; record date July 18, 2025.
Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort
Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.
Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development
Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.
Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial
Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.
2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.
Phio Pharmaceuticals dismisses BDO and engages Grant Thornton as auditor
Audit Committee dismissed BDO USA as independent auditor effective April 17, 2025.
Phio gets SMC nod to advance PH-762 skin cancer trial to 4th dose cohort
Safety Monitoring Committee recommended dose escalation to fourth cohort in Phase 1b trial (NCT06014086).
Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised
Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.
Phio Pharmaceuticals appoints David H. Deming to Board of Directors, effective Feb 19, 2025
Board expanded to six members; five of six are independent directors.
Phio raises $1.83M via registered direct offering and warrant private placement
Sold 610,000 shares at $3.00 each; issued warrants for 1,220,000 shares at $3.00 exercisable for 24 months.
Gross proceeds of $2.5M; net ~$2.2M after fees and expenses.
Phio raises $3.19M in registered direct offering and warrant placement
Gross proceeds of $3.19M; net ~$2.85M after fees and expenses.
2 of 4 patients in 2nd cohort achieved 100% tumor clearance (complete response).
Phio raises ~$0.48M in registered direct offering of 240K shares at $2.00/share with warrants
Sold 240,000 shares of common stock at $2.00/share for gross proceeds of ~$0.48M; net ~$0.48M after expenses.
Phio Pharma raises ~$1.15M in registered direct offering & private placement
Gross proceeds ~$1.15M; net proceeds ~$900K after fees and expenses.
Safety Monitoring Committee reviewed safety data from second dose cohort and recommended escalation to next dose concentration.
Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient
Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.
Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients
Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.
Phio Pharma Q2 net loss $1.8M, cash $4.7M; PH-762 trial progresses
Cash at June 30, 2024: $4.7M vs $8.5M at Dec 31, 2023; net loss $1.8M vs $2.5M year ago.
Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024
Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.
Phio Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse split
Received Nasdaq notice on July 19, 2024, confirming compliance with Listing Rule 5550(a)(2).
Phio Pharmaceuticals raises $3.1M via warrant exercise at $5.45/share; issues new warrants
Gross proceeds ~$3.1M from cash exercise of 545,286 existing warrants at reduced price of $5.45/share (original range $324-$9.72).
Phio terminates $621K share purchase agreement with Triton Funds after stock falls below floor
On July 3, 2024, Phio terminated the Purchase Agreement with Triton Funds LP, effective immediately.
Phio Pharmaceuticals implements 1-for-9 reverse stock split effective July 5, 2024
Reverse split ratio set at 1-for-9; reduces outstanding shares from ~4.6M to ~0.5M.
Phio shareholders approve reverse stock split (1:2-1:9) and 500K share increase to LTIP
Reverse stock split proposal approved with 1,879,666 For, 313,572 Against; board to set exact ratio and effective date.
Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities
Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.
Phio Pharmaceuticals enters purchase agreement with Triton Funds for up to $621k at $0.72 per share
Up to 862,500 shares at $0.72/share, representing ~18.8% of outstanding shares.
Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M
Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.
Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress
Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.
Phio Pharmaceuticals receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq deficiency notice on Jan 24, 2024; stock failed to maintain $1.00 minimum bid for 30 consecutive business days.
Effective as of July 20, 2026, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders.
Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.
designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.
Effective as of February 19, 2025, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed Mr. David H. Deming to serve on the Board until the 2025 annual meeting of stockholders.
Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.
On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.
On February 17, 2023, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert J. Bitterman, acting Executive Chairman of the Board and acting Interim Chief Executive Officer, to serve as the Company’s President and Chief Executive Officer and Chair of the Board, effective as of February 20, 2023.
Dr. Geert Cauwenbergh, a member of the Company’s Board, will no longer serve as the Company’s interim principal executive officer and interim principal financial officer, which positions he held since May 4, 2022.
approved the appointment of Robert J. Bitterman, Chairman of the Company’s Board, to serve as the Company’s interim Executive Chairman, effective immediately.
On May 5, 2022, Phio Pharmaceuticals Corp. (the “Company”) announced the departure of Gerrit Dispersyn, Dr. Med. Sc., from his role as President and Chief Executive Officer of the Company, effective as of May 5, 2022
On May 4, 2022, the Board appointed Geert Cauwenbergh, Dr. Med. Sc., as the Company’s interim principal executive and financial officer, effective as of May 5, 2022.
Effective as of April 27, 2022, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to eight members and appointed Patricia A. Bradford, former Senior Vice President Global Human Resources, Unisys Corporation, to serve on the Board until the 2022 annual meeting of stockholders.
Max materiality 0.90 · Median 0.62 · Most common event other_material